Mass spectrometry raw data for the manuscript Multi-omics analysis reveals attenuation of cellular stress by Empagliflozin in High Glucose-treated human cardiomyocytes
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Abstract Background Sodium-glucose co-transporters (SGLT) inhibitors (SGLT2i) showed many beneficial...
Sodium-glucose-cotransporter-2 (SGLT2) inhibitors showed favourable cardiovascular outcomes, but the...
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Abstract Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we exami...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse p...
International audienceAbstract Background Sodium glucose co-transporter 2 (SGLT2) inhibitors improve...
BackgroundType 2 diabetes mellitus is a high-risk factor for acute cardiovascular events. Some repor...
The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently re...
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Abstract Background Sodium-glucose co-transporters (SGLT) inhibitors (SGLT2i) showed many beneficial...
Sodium-glucose-cotransporter-2 (SGLT2) inhibitors showed favourable cardiovascular outcomes, but the...
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Abstract Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
To explore mechanisms by which SGLT2 inhibitors protect diabetic hearts from heart failure, we exami...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as novel cardioprotective ag...
Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse p...
International audienceAbstract Background Sodium glucose co-transporter 2 (SGLT2) inhibitors improve...
BackgroundType 2 diabetes mellitus is a high-risk factor for acute cardiovascular events. Some repor...
The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently re...
International audienceAbstract Diabetes mellitus (DM)-induced cardiac morbidities have been the lead...
Abstract Background Sodium-glucose co-transporters (SGLT) inhibitors (SGLT2i) showed many beneficial...
Sodium-glucose-cotransporter-2 (SGLT2) inhibitors showed favourable cardiovascular outcomes, but the...
DOI
Add to ORKG